Key Takeaways in HER2-Mutated NSCLC
The panel concludes the discussion with key takeaways on the evolving treatment landscape in HER2 non–small cell lung cancer.
Read More
Treatment Considerations in HER2-Mutated NSCLC
Experts on HER2 NSCLC provide clinical insights on selecting between antibody-drug conjugates and TKIs, treatment sequencing, and the role of chemoimmunotherapy.
Read More
Challenges and Unmet Needs in HER2-Mutated NSCLC
The expert panel shares its thoughts on current challenges and unmet needs in the overall HER2-mutated non–small cell lung cancer treatment landscape.
Read More
Adverse Events Associated With TKIs in HER2-Mutated NSCLC
D. Ross Camidge, MD, PhD, discusses the main adverse events seen with TKIs in patients with HER2-mutated non–small cell lung cancer.
Read More
First-in-Human Study of BAY2927088 in Advanced HER2-Mutated NSCLC
Martin Dietrich, MD, PhD, provides an overview of the first-in-human study of BAY2927088, a novel TKI, in patients with advanced HER2-mutated non–small cell lung cancer.
Read More
Beamion LUNG-1: Zongertinib in Advanced HER2-Mutated NSCLC
The panel offers comprehensive insights on the Beamion LUNG-1 clinical trial, which is investigating zongertinib in patients with advanced HER2-mutated non–small cell lung cancer.
Read More
The Potential Role of TKIs in HER2-Mutated NSCLC
Edward Kim, MD, MBA, describes the potential role of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2-mutated non–small cell lung cancer.
Read More
Managing Adverse Events Associated With ADCs in HER2-Mutated NSCLC
Lyudmila A. Bazhenova, MD, an expert on non–small cell lung cancer, provides clinical insights on the management of adverse events associated with antibody-drug conjugates.
Read More
DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC
Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2-mutated NSCLC.
Read More
The Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC
Experts on HER2-mutated NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.
Read More
DESTINY-Lung01 & DESTINY-Lung02: T-DXd in Metastatic HER2-Mutated NSCLC
Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.
Read More
Role of ADCs in HER2-Mutated NSCLC
The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2-mutated non–small cell lung cancer.
Read More
Biomarker Testing Challenges in HER2-mutated NSCLC
Experts on HER2-mutated non–small cell lung cancer provide clinical insights on biomarker testing challenges and the role of reflex testing.
Read More
A panel of thoracic oncologists introduce themselves and discuss biomarker testing strategies and the diagnosis of HER2-mutated non–small cell lung cancer (NSCLC).
Read More
Dr Bazhenova on the Need for Comprehensive Molecular Testing in Unresectable NSCLC
January 18th 2024Lyudmila A. Bazhenova, MD, discusses key factors in the management of unresectable non–small cell lung cancer, emphasizing the importance of understanding and performing biomarker testing in this population.
Read More
Dr Bazhenova on Perioperative Treatment Selection in EGFR– or ALK-Mutated NSCLC
December 1st 2023Lyudmila A. Bazhenova, MD, discusses factors to consider when navigating the use of neoadjuvant vs adjuvant EGFR– and ALK-directed treatment strategies for patients with non–small cell lung cancer who express oncogenic drivers.
Read More
Dr Bazhenova on Addressing Potential Gaps in the Treatment of Lung Cancer Care
October 26th 2023Lyudmila A. Bazhenova, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, expanding on the hope to confirm a consensus on how to best move forward to address gaps in lung cancer care.
Read More
Dr Bazhenova on Treating Patients With Advanced NSCLC Harboring EGFR Mutations
September 6th 2023Lyudmila A. Bazhenova, MD, discusses how to treat patients with non–small cell lung cancer who present with EGFR mutations, highlights how to accurately pinpoint gaps in lung cancer care, and expands on how to address these gaps in patients with non–small cell lung cancer.
Read More